(Total Views: 905)
Posted On: 08/30/2021 11:21:06 AM
Post# of 153916
Cycl2R,
both CD17 (moderate) and CD16 (critical) are approved, with the delay reported to be due to importation hurdles.
I spent the weekend looking at that in multiple spots throughout the gov.br constellation of webpages and it appears complex with multiple steps.
That being said, this is the purpose for which Biomm was hired, as A.Einstein conducting the trials.
In Portugese, but here is the relevant page noting approval of the Leronlimab trials in Brazil.
I am not familiar with CD19. Is that P3 LH/PASC?
PDF available here:
https://www.gov.br/anvisa/pt-br/assuntos/medi...8.2021.pdf
both CD17 (moderate) and CD16 (critical) are approved, with the delay reported to be due to importation hurdles.
I spent the weekend looking at that in multiple spots throughout the gov.br constellation of webpages and it appears complex with multiple steps.
That being said, this is the purpose for which Biomm was hired, as A.Einstein conducting the trials.
In Portugese, but here is the relevant page noting approval of the Leronlimab trials in Brazil.
I am not familiar with CD19. Is that P3 LH/PASC?
PDF available here:
https://www.gov.br/anvisa/pt-br/assuntos/medi...8.2021.pdf
(8)
(0)
